» Articles » PMID: 36631483

Metabolomics-based Study of Potential Biomarkers of Sepsis

Overview
Journal Sci Rep
Specialty Science
Date 2023 Jan 11
PMID 36631483
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of our study was to explore potential characteristic biomarkers in patients with sepsis. Peripheral blood specimens from sepsis patients and normal human volunteers were processed by liquid chromatography-mass spectrometry-based analysis. Outlier data were excluded by principal component analysis and orthogonal partial least squares-discriminant analysis using the metabolomics R software package metaX and MetaboAnalyst 5.0 ( https://www.metaboanalyst.ca/home.xhtml ) online analysis software, and differential metabolite counts were identified by using volcano and heatmaps. The obtained differential metabolites were combined with KEGG (Kyoto Gene and Kyoto Encyclopedia) analysis to screen out potential core differential metabolites, and ROC curves were drawn to analyze the changes in serum metabolites in sepsis patients and to explore the potential value of the metabolites in the diagnosis of sepsis patients. By metabolomic analysis, nine differential metabolites were screened for their significance in guiding the diagnosis and differential diagnosis of sepsis namely: 3-phenyl lactic acid, N-phenylacetylglutamine, phenylethylamine, traumatin, xanthine, methyl jasmonate, indole, l-tryptophan and 1107116. In this study, nine metabolites were finally screened based on metabolomic analysis and used as potential characteristic biomarkers for the diagnosis of sepsis.

Citing Articles

Targeting Metabolic and Epigenetic Vulnerabilities in Glioblastoma with SN-38 and Rabusertib Combination Therapy.

Chiou J, Impedovo V, Huynh Y, Gorgoglione R, Penalva L, Lodi A Int J Mol Sci. 2025; 26(2).

PMID: 39859189 PMC: 11764980. DOI: 10.3390/ijms26020474.


Therapeutic potential of Xihuang Pill in colorectal cancer: Metabolomic and microbiome-driven approaches.

Zhang C, Sui C, Ma X, Ma C, Sun X, Zhai C Front Pharmacol. 2024; 15:1402448.

PMID: 39687297 PMC: 11646767. DOI: 10.3389/fphar.2024.1402448.


Platelet Metabolites as Candidate Biomarkers in Sepsis Diagnosis and Management Using the Proposed Explainable Artificial Intelligence Approach.

Yagin F, Aygun U, Algarni A, Colak C, Al-Hashem F, Ardigo L J Clin Med. 2024; 13(17).

PMID: 39274215 PMC: 11395774. DOI: 10.3390/jcm13175002.


Targeted Analysis of Plasma Polar Metabolites in Postmenopausal Depression.

Naufel M, Pedroso A, de Souza A, Boldarine V, Oyama L, Lo Turco E Metabolites. 2024; 14(5).

PMID: 38786763 PMC: 11123176. DOI: 10.3390/metabo14050286.


Integrating Routine Hematological and Extended Inflammatory Parameters as a Novel Approach for Timely Diagnosis and Prognosis in Sepsis Management.

Herawati S, Somia I, Kosasih S, Wande I, Felim J, Payana I Diagnostics (Basel). 2024; 14(9).

PMID: 38732370 PMC: 11083944. DOI: 10.3390/diagnostics14090956.


References
1.
Pammi M, Flores A, Versalovic J, Leeflang M . Molecular assays for the diagnosis of sepsis in neonates. Cochrane Database Syst Rev. 2017; 2:CD011926. PMC: 6464551. DOI: 10.1002/14651858.CD011926.pub2. View

2.
Tan Y, Gao Y, Teo G, Koh H, Tai E, Khoo C . Plasma Metabolome and Lipidome Associations with Type 2 Diabetes and Diabetic Nephropathy. Metabolites. 2021; 11(4). PMC: 8069978. DOI: 10.3390/metabo11040228. View

3.
Sharma D, Farahbakhsh N, Shastri S, Sharma P . Biomarkers for diagnosis of neonatal sepsis: a literature review. J Matern Fetal Neonatal Med. 2017; 31(12):1646-1659. DOI: 10.1080/14767058.2017.1322060. View

4.
Li C, Li Y, Sui L, Wang J, Li F . Phenyllactic acid promotes cell migration and invasion in cervical cancer via IKK/NF-κB-mediated MMP-9 activation. Cancer Cell Int. 2019; 19:241. PMC: 6757389. DOI: 10.1186/s12935-019-0965-0. View

5.
Vincent J . The Clinical Challenge of Sepsis Identification and Monitoring. PLoS Med. 2016; 13(5):e1002022. PMC: 4871479. DOI: 10.1371/journal.pmed.1002022. View